TWIST1 GENE EXPRESSION AS A BIOMARKER FOR PREDICTING PRIMARY DOXORUBICIN RESISTANCE IN BREAST CANCER

Basit Öğe Kaydı
dc.authoridMuslumanoglu, Muhammed Hamza/0000-0002-6210-648X
dc.authoridCakir, Tunahan/0000-0001-8262-4420
dc.authoridArtan, Sevilhan/0000-0001-7658-6309
dc.authorwosidMuslumanoglu, Muhammed Hamza/AAZ-9070-2020
dc.authorwosidAydiner, Adnan/AAU-4591-2020
dc.authorwosidDemir, Selma/A-1500-2018
dc.authorwosidCakir, Tunahan/F-4523-2011
dc.authorwosidBasaran, Seher/AAC-5463-2020
dc.authorwosidArtan, Sevilhan/AEG-2575-2022
dc.contributor.authorDemir, S.
dc.contributor.authorMuslumanoglu, M. H.
dc.contributor.authorMuslumanoglu, M.
dc.contributor.authorBasaran, S.
dc.contributor.authorCalay, Z. Z.
dc.contributor.authorAydiner, A.
dc.contributor.authorVogt, U.
dc.date.accessioned2024-06-12T10:54:39Z
dc.date.available2024-06-12T10:54:39Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractDoxorubicin is one of the most commonly used chemotherapeutic agents for adjuvant chemotherapy of breast cancer. In the studies focused on finding biomarkers to predict the response of the patients and tumors to the drugs used, the Twist transcription factor has been suggested as a candidate biomarker for predicting chemo-resistance of breast tumors. In this study, we aimed to investigate the relationship between TWIST transcription factor expression and the effectiveness of doxorubicin treatment on directly taken primary tumor samples from chemotherapy-naive breast cancer patients. Twenty-six primary breast tumor samples taken from 26 different breast cancer patients were included in this study. Adenosine triphosphate tumor chemo-sensitivity assay (ATP-TCA) has been used to determine tumor response to doxorubicin and real-time reverse-transcription polymerase chain reaction (RT-PCR) was used for analyzing the TWIST1 gene expression of tumors. There was a significant difference in TWIST gene expression between responder and non responder tumors (p <0.05). The TWIST gene expression of the drug-resistant group was higher than the responsive group. This difference was not dependent on the histopathological features of tumors. In conclusion, compatible with earlier studies that have been performed with cell lines, the current study supports the role of higher TWIST gene expression as a biomarker for predicting the response of breast tumors to chemo-therapeutic agent doxorubicin.en_US
dc.identifier.doi10.2478/bjmg-2019-0025
dc.identifier.endpage30en_US
dc.identifier.issn1311-0160
dc.identifier.issue2en_US
dc.identifier.pmid31942413en_US
dc.identifier.scopus2-s2.0-85078207236en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage25en_US
dc.identifier.urihttps://doi.org/10.2478/bjmg-2019-0025
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19130
dc.identifier.volume22en_US
dc.identifier.wosWOS:000503866600003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMacedonian Acad Sciences Artsen_US
dc.relation.ispartofBalkan Journal Of Medical Geneticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiomanceren_US
dc.subjectBreast Canceren_US
dc.subjectChemotherapyen_US
dc.subjectExpressionen_US
dc.subjectTWIST1 Geneen_US
dc.subjectMultidrug-Resistanceen_US
dc.subjectIn-Vitroen_US
dc.subjectChemosensitivityen_US
dc.subjectCellsen_US
dc.subjectCytotoxicityen_US
dc.subjectSensitivityen_US
dc.subjectCombinationen_US
dc.titleTWIST1 GENE EXPRESSION AS A BIOMARKER FOR PREDICTING PRIMARY DOXORUBICIN RESISTANCE IN BREAST CANCERen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu